Mediterranean Spotted Fever - Classification by Disease Course and Criteria for Determining the Disease Severity

Open access


INTRODUCTION: Mediterranean spotted fever (MSF) in Bulgaria is caused by Ricketsia

conorii conorii with a major vector the dog tick, Rhipicephalus sanguineus. The first cases of re-emerging MSF were reported in this country in the early 1990s after some 20 years of absence and then registered an annual increase until 2001-2003 after which the disease prevalence declined. MSF still poses a serious health problem in the country as severe, complicated cases with lethal outcome occur.

The AIM of this paper was to classify the forms of MSF according to the course of the disease process and to devise criteria for the disease severity in order to enable comparison of clinical manifestations of the disease at different stages of spreading, in different age groups, and between endemic and non-endemic regions in this country and abroad.

PATIENTS AND METHODS: The study was carried out in a comparative aspect during the first phase of increase (1993-2003) with incidence of 11.88 per 100000 population and during the second phase of decline (2004-2011) with incidence of 9.56 per 100000 population. The disease was etiologically confirmed in 883 hospitalized patients by the positive antibody response to the specific antigen - Ricketsia conorii conorii by means of the immunofluorescence assay (IFA). The criteria we used for the classification of the forms of MSF included:

1. Typicality: forms having the most characteristic features of the MSF - eschar, fever, papular / maculopapular rash on the trunk and extremities, including hands and feet.

2. Manifestation: forms represented by all or some of the typical symptoms, giving sufficient grounds for preliminary diagnosis.

3. Duration: fulminant, acute and protracted forms.

The criteria for severity differentiate between mild, moderate, severe or malignant forms, and include clinical and laboratory parameters as shown in the present study.

RESULTS: Classification of the forms according to MSF course defines them in order of severity, typicality, manifestation, duration of symptoms, complications and age characteristics. According to the accepted criteria for severity and with respect to the studied I and II phase of the disease the mild forms are 41.16% - 35.62% (p > 0.05), moderate forms are 32.79% - 43.11% (p < 0.01), severe forms are 16.03% - 11.37% (p = 0.05), malignant forms are 6.56% - 8.68% (p > 0.05), and mortality is 3.46% - 1.19% (p < 0.05). The mean age was significantly higher for patients with severe forms of MSF (58.59 ± 4.32 yrs) compared with those with moderate (46.10 ± 3.71 yrs, p < 0.05) and mild forms (42.05 ± 3.50 yrs, p < 0.01). For children up to 14 years old mild forms are more common than in adults over 65 (p < 0.0001). Among children up to 14 years old there were no lethal outcomes, while mortality rate in the patients older than 65 was as much as 10%. All this indicates that MSF runs a milder course in children and a severe, complicated course in the elderly.

CONCLUSION: The criteria for MSF severity we have selected are based on our own experience and the experience of other authors. They are based on the reaction of human organism to the pathogenic agent and can be used during the different phases of emergence and development of rikettsial diseases, regardless of their geographic distribution. Unified use of these criteria would eliminate the differences in the data reported by different researchers regarding the disease development and severity.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Vapzarov I. About a small epidemic of Fievre boutonneuse in Plovdiv region Bulgaria. Zdravno delo 1948;1:21-9 (Bulgarian).

  • 2. Serbesov V Alexandrov E. Active influencing of the epidemiological process of Marseille fever in Bulgaria. J Hig Epidemiol Microbiol Immunol 1973; 17:445-52.

  • 3. Rovery C Brouqui P Raoult D. Questions on Mediterranean spotted fever a century after its discovery. Emerg Infect Dis 2008;14:1360-7.

  • 4. Mansueto S Tringali G Di Leo R Maniscalco M Montenegro MR Walker DH. Demonstration of spotted fever group rickettsiae in the tache noire of a healthy person in Sicily. Am J Trop Med Hyg 1984;33(3):479-82.

  • 5. Mansueto S Vitale G Miceli MD Tringali G et al. A sero-epidemiological survey of asymptomatic cases of boutonneuse fever in western Sicily. Trans R Soc Trop Med Hyg 1984;78:16-18.

  • 6. Herrero-Herrero JI Ruiz Beltran R Martin Sanchez AM. Naturally acquired immunity: a means of resistance to Mediterranean spotted fever? J Infect Dis 1991;164(3):618-9.

  • 7. Castella X Villar T Badal J Pons R Gilabert J Torres C Torner F. Malignant Mediterranean boutonneuse fever. Septic shock of unknown origin? Rev Clin Esp 1991;188(4):199-201.

  • 8. Popivanova N Baltadzhiev I Zaprianov Z. Mediterranean spotted fever in the Plovdiv region of Bulgaria. In: Contemporary state of the rickettsioses in the world and in Bulgaria. Alexandrov E Kazar J Hechemy K Kantardjiev T еditors. Sofia: Prof. Marin Drinov Academic Publishing House; 2007:116-130 (Bulgarian).

  • 9. Walker D. Biology of rickettsial diseases. Boca Raton FL:CRC Press;1988:79-100.

  • 10. Demeester R Claus M Hildebrand M Vlieghe E Bottieau E. Diversity of life-threatening complications due to Mediterranean spotted fever in returning travelers. J Travel Med 2010;17(2):100-4.

  • 11. Soriano V Sabria M Davins J Manterola JM. Complications in Mediterranean boutonneuse fever: prospective study of 78 patients. Rev Clin Esp 1989;184(9):459-63.

  • 12. Raoult D Kohler JL Gallais H De Micco P Rousseau S Casanova P. Fatal rickettsiosis. Nouv Presse Med 1982;11(8):607.

  • 13. Colomba C Saporito L Siracusa L Giammanco G Bonura S Titone L. Mediterranean spotted fever in paediatric and adult patients: two clinical aspects of the same disease. Infez Med 2011;19(4):248-53.

  • 14. Sousa R França A Dória Nòbrega S Belo A Amaro M Abreu T et al. Host- and microbe-related risk factors for and pathophysiology of fatal Rickettsia conorii infection in Portuguese patients. J Infect Dis 2008;198(4):576-85.

  • 15. Valbuena G Walker DH. Infection of the endothelium by members of the order rickettsiales. Thromb Haemost 2009;102:1071-9.

  • 16. Sahni SK Rydkina E. Host-cell interaction with pathogenic Rickettsia sp. Future Microbiol 2009;4:323-39.

  • 17. Walker DH. Rickettsiae and Rickettsial infections: the current state of knowledge. Clin Infect Dis 2007;45:S39-S44.

  • 18. Sousa R Nobrega SD Bacellar F Torgal J. Mediterranean spotted fever in Portugal: risk factors for fatal outcome in 105 hospitalized patients. Ann NY Acad Sci 2003;990:285-94.

  • 19. Sousa R Ismail N Dória-Nóbrega S et al. The presence of eschars but not greater severity in Portuguese patients infected with Israeli spotted fever. Ann NY Acad Sci 2005;1063:197-202.

  • 20. Fournier PE Raoult D. Intraspecies diversity of Rickettsia conorii. J Infect Dis 2009;199(7):1097-8.

  • 21. George F Brouqui P Boffa MC Mutin M Drancourt M Brisson C et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells thrombomodulin and von Willebrand factor in patients with Mediterranean spotted fever. Blood 1993;82(7):2109-16.

  • 22. Roult D Zuchelli P Weiller PJ Charrel C San Marco JL Gallais H Casanova P. Incidence clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984. J Infect 1986;12(2):111-6.

  • 23. Dignat-George F Tissot-Dupon H Grau G et al. Differences in levels of soluble E-selectin and VCAM-1 in malignant versus non malignant Mediterranean spotted fever. Thromb Haemost 1999;82:1610-3.

  • 24. Fgueira J Martins T Machado J Maltez F. Atypical case of Mediterranean spotted fever. Braz J Infect Dis 2010;14(3):213-6.

  • 25. Alioua Z Bourazza A Lamsyah H et al. Neurological feature of Mediterranean spotted fever: a study of four cases. Rev Med Intern 2003;24(12):824-9.

  • 26. Fang R Ismail N Shelite T Walker DH. CD4+ CD25+ Foxp3- T-regulatory cells produce both gamma interferon and interleukin-10 during acute severe murine spotted fever rickettsiosis. Infect Immun 2009;77(9):3838-49.

  • 27. Walker DH Ismail N. Emerging and re-emerging rickettsioses: endothelial cell infection and early disease events. Nat Rev Microbiol 2008;6:375-86.

  • 28. Popivanova N M. Murdjeva I. Baltadzhiev I. Haydushka. Dynamics in serum cytokine responses during Mediterranean spotted fever acute and convalescent stages. Folia Medica 2011;53(2):36-43.

  • 29. Baltadzhiev I. Clinical epidemiological and pathogenetic aspects of the tick-borne rickettsiosis Mediterranean spotted fever. [Dissertation] Medical University-Plovdiv Bulgaria; 2012 (Bulgarian).

  • 30. Forte GI Scola L Misiano G Milano S Mansueto P Vitale G et al. Relevance of gamma interferon tumor necrosis factor alpha and interleukin-10 gene polymorphisms to susceptibility to Mediterranean spotted fever. Clin Vaccine Immunol 2009;(6):811-5.

Journal information
Impact Factor

CiteScore 2018: 0.587

SCImago Journal Rank (SJR) 2018: 0.311

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 142 66 3
PDF Downloads 74 38 1